Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nivolumab in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06794229 Clinical Landscape Report 2026
15 October 2026
NCT06794229 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
BCMA-CD19 CAR-T(Peking University People's Hospital) in Behcet Syndrome: NCT06794008 Clinical Landscape Report 2026
15 October 2026
NCT06794008 clinical landscape for Behcet Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme) in Acute Myeloid Leukemia: NCT06793410 Clinical Landscape Report 2026
15 October 2026
NCT06793410 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Triple Negative Breast Cancer: NCT06793332 Clinical Landscape Report 2026
15 October 2026
NCT06793332 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Patritumab Deruxtecan in Breast Cancer: NCT06797635 Clinical Landscape Report 2026
15 October 2026
NCT06797635 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IBI-363 in Mucosal Melanoma: NCT06797297 Clinical Landscape Report 2026
15 October 2026
NCT06797297 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ADCE-D01 in Metastatic Soft Tissue Sarcoma: NCT06797999 Clinical Landscape Report 2026
15 October 2026
NCT06797999 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ATX-295 in Locally Advanced Malignant Solid Neoplasm: NCT06799065 Clinical Landscape Report 2026
15 October 2026
NCT06799065 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Docetaxel in Triple Negative Breast Cancer: NCT06795503 Clinical Landscape Report 2026
15 October 2026
NCT06795503 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGN-CD228A in Metastatic melanoma: NCT06799533 Clinical Landscape Report 2026
15 October 2026
NCT06799533 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VIS171 in Alopecia Areata: NCT06799520 Clinical Landscape Report 2026
15 October 2026
NCT06799520 clinical landscape for Alopecia Areata: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06803693 Clinical Landscape Report 2026
15 October 2026
NCT06803693 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.